NO20005673D0 - Heterocykliske inhibitorer av P38 - Google Patents
Heterocykliske inhibitorer av P38Info
- Publication number
- NO20005673D0 NO20005673D0 NO20005673A NO20005673A NO20005673D0 NO 20005673 D0 NO20005673 D0 NO 20005673D0 NO 20005673 A NO20005673 A NO 20005673A NO 20005673 A NO20005673 A NO 20005673A NO 20005673 D0 NO20005673 D0 NO 20005673D0
- Authority
- NO
- Norway
- Prior art keywords
- heterocyclic inhibitors
- heterocyclic
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/01—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products based on oxide ceramics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Ceramic Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Structural Engineering (AREA)
- Obesity (AREA)
- Manufacturing & Machinery (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8505398P | 1998-05-11 | 1998-05-11 | |
US12762699P | 1999-04-01 | 1999-04-01 | |
US12909999P | 1999-04-13 | 1999-04-13 | |
PCT/US1999/010291 WO1999058502A1 (en) | 1998-05-11 | 1999-05-11 | Heterocyclic inhibitors of p38 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20005673D0 true NO20005673D0 (no) | 2000-11-10 |
NO20005673L NO20005673L (no) | 2001-01-10 |
NO319755B1 NO319755B1 (no) | 2005-09-12 |
Family
ID=27375001
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20005673A NO319755B1 (no) | 1998-05-11 | 2000-11-10 | Heterocykliske inhibitorer av P38 |
Country Status (31)
Country | Link |
---|---|
US (4) | US6632945B2 (no) |
EP (3) | EP2336111A1 (no) |
JP (2) | JP4704560B2 (no) |
KR (1) | KR100696219B1 (no) |
CN (1) | CN1306512A (no) |
AP (1) | AP2000001996A0 (no) |
AT (1) | ATE417828T1 (no) |
AU (1) | AU764047B2 (no) |
BG (1) | BG65025B1 (no) |
BR (1) | BR9911786A (no) |
CA (1) | CA2331460C (no) |
CZ (1) | CZ300702B6 (no) |
DE (1) | DE69940115D1 (no) |
DK (1) | DK1077943T3 (no) |
EA (1) | EA200001176A1 (no) |
EE (1) | EE200000610A (no) |
ES (1) | ES2318893T3 (no) |
GE (1) | GEP20032954B (no) |
HK (1) | HK1034907A1 (no) |
HU (1) | HUP0105174A3 (no) |
IL (2) | IL139479A0 (no) |
IS (1) | IS5711A (no) |
MY (1) | MY132496A (no) |
NO (1) | NO319755B1 (no) |
NZ (1) | NZ508653A (no) |
PL (1) | PL198352B1 (no) |
PT (1) | PT1077943E (no) |
SK (1) | SK286689B6 (no) |
TW (1) | TWI249527B (no) |
UA (1) | UA74325C2 (no) |
WO (1) | WO1999058502A1 (no) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6608060B1 (en) * | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US20020156104A1 (en) | 1997-06-13 | 2002-10-24 | Jerry L. Adams | Novel pyrazole and pyrazoline substituted compounds |
ID23777A (id) | 1997-09-10 | 2000-05-11 | Dainippon Ink & Chemicals | Turunan 2, 6-dikloro-4-piridinametanol dan kimia-kimia pertanian |
US6469018B1 (en) | 1999-01-08 | 2002-10-22 | Smithkline Beecham Corporation | Compounds |
ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
RU2260592C9 (ru) | 1999-04-15 | 2017-04-07 | Бристол-Маерс Сквибб Ко. | Циклические ингибиторы протеинтирозинкиназ |
AU5316900A (en) * | 1999-06-03 | 2000-12-28 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) |
AU1781601A (en) | 1999-11-23 | 2001-06-04 | Smithkline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
EP1259486A1 (en) | 2000-02-23 | 2002-11-27 | Iconix Pharmaceuticals, Inc. | Pyridine-amidines as modulators of p38 map kinase |
MXPA02009319A (es) * | 2000-03-22 | 2003-03-12 | Vertex Pharma | Inhibidores de p38. |
AU8323701A (en) * | 2000-08-11 | 2002-02-25 | John Cochran | Inhibitors of p38 |
US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
US7271181B2 (en) | 2001-05-11 | 2007-09-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
EP2036891A3 (en) | 2001-06-11 | 2009-03-25 | Vertex Pharmaceuticals Incorporated | Isoquinoline inhibitors of P38 |
HUP0401711A3 (en) * | 2001-06-26 | 2009-07-28 | Bristol Myers Squibb Co | N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them |
DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
GB0214268D0 (en) * | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
CA2492033A1 (en) | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
AU2004212494B2 (en) | 2003-02-10 | 2011-03-17 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of N-heteroaryl-N-aryl-amines by reacting an N-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
EP1742936A2 (en) | 2004-04-13 | 2007-01-17 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
KR100575344B1 (ko) * | 2004-07-14 | 2006-05-03 | 주식회사 이큐스팜 | C형 간염 예방 및 치료용 약학적 조성물 |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
WO2006021848A1 (en) * | 2004-08-27 | 2006-03-02 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
US8017395B2 (en) | 2004-12-17 | 2011-09-13 | Lifescan, Inc. | Seeding cells on porous supports |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
AU2006202209B2 (en) | 2005-05-27 | 2011-04-14 | Lifescan, Inc. | Amniotic fluid derived cells |
BRPI0502016B8 (pt) * | 2005-06-03 | 2021-05-25 | Univ Federal Do Rio De Janeiro Ufrj | composto ureídicos, composições farmacêuticas contendo os mesmos e seu uso no tratamento de doenças inflamatórias |
CN101484575B (zh) * | 2005-06-08 | 2013-10-02 | 森托科尔公司 | 用于眼变性的细胞疗法 |
US20070122448A1 (en) * | 2005-11-28 | 2007-05-31 | Alireza Rezania | Compositions and methods to create a vascularized environment for cellular transplantation |
US8741643B2 (en) | 2006-04-28 | 2014-06-03 | Lifescan, Inc. | Differentiation of pluripotent stem cells to definitive endoderm lineage |
ES2725601T3 (es) | 2006-04-28 | 2019-09-25 | Lifescan Inc | Diferenciación de células madre embriónicas humanas |
CN101641436A (zh) * | 2007-01-30 | 2010-02-03 | 佐治亚大学研究基金会 | 用于产生内胚层和中胚层细胞系及多能游走细胞(mmc)的早期中胚层细胞即稳定的中内胚层细胞群 |
EP2131858A4 (en) * | 2007-03-20 | 2011-11-23 | Cadila Pharmaceuticals Ltd | P38 INHIBITORS |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
US9080145B2 (en) | 2007-07-01 | 2015-07-14 | Lifescan Corporation | Single pluripotent stem cell culture |
CA2693156C (en) | 2007-07-18 | 2018-03-06 | Alireza Rezania | Differentiation of human embryonic stem cells |
WO2009018453A1 (en) | 2007-07-31 | 2009-02-05 | Lifescan, Inc. | Differentiation of human embryonic stem cells |
CA3123528A1 (en) | 2007-11-27 | 2009-06-04 | Lifescan, Inc. | Differentiation of human embryonic stem cells to pancreatic cells |
KR20190057164A (ko) * | 2008-02-21 | 2019-05-27 | 얀센 바이오테크 인코포레이티드 | 세포 부착, 배양 및 탈리를 위한 방법, 표면 개질 플레이트 및 조성물 |
US8623648B2 (en) * | 2008-04-24 | 2014-01-07 | Janssen Biotech, Inc. | Treatment of pluripotent cells |
ES2697798T3 (es) | 2008-06-30 | 2019-01-28 | Janssen Biotech Inc | Diferenciación de células madre pluripotentes |
US20110305672A1 (en) | 2008-07-25 | 2011-12-15 | University Of Georgia Research Foundation, Inc. | COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME |
WO2010011352A2 (en) | 2008-07-25 | 2010-01-28 | The University Of Georgia Research Foundation, Inc. | Compositions for mesoderm derived isl1+ multipotent cells (imps), epicardial progenitor cells (epcs) and multipotent cxcr4+cd56+ cells (c56cs) and methods of use |
US20100028307A1 (en) * | 2008-07-31 | 2010-02-04 | O'neil John J | Pluripotent stem cell differentiation |
WO2010038428A1 (ja) * | 2008-09-30 | 2010-04-08 | 武田薬品工業株式会社 | タキサン系抗がん剤の置き換え薬 |
RU2522001C2 (ru) | 2008-10-31 | 2014-07-10 | Сентокор Орто Байотек Инк. | Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток |
BRPI0919883A2 (pt) | 2008-10-31 | 2015-08-11 | Centocor Ortho Biotech Inc | Diferenciação de células-tronco embrionárias humanas para a linhagem endócrina pancreática |
WO2010059778A1 (en) * | 2008-11-20 | 2010-05-27 | Centocor Ortho Biotech Inc. | Methods and compositions for cell attachment and cultivation on planar substrates |
KR101837080B1 (ko) | 2008-11-20 | 2018-03-09 | 얀센 바이오테크 인코포레이티드 | 마이크로-캐리어 상의 만능 줄기 세포 배양 |
CN102356066A (zh) * | 2008-12-10 | 2012-02-15 | 同和药品株式会社 | 新型2,6-取代的-3-硝基吡啶衍生物、其制备方法及包含有其的药物组合物 |
CN102317442B (zh) | 2008-12-17 | 2014-08-13 | 斯克里普斯研究所 | 干细胞的产生和保持 |
EP2396302A2 (en) * | 2009-02-13 | 2011-12-21 | Vertex Pharmceuticals Incorporated | Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides) |
GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
BR112012001564A2 (pt) * | 2009-07-20 | 2015-09-01 | Janssen Biotech Inc | Diferenciação de células tronco embrionárias humanas. |
GB2484873B (en) | 2009-07-20 | 2014-04-30 | Janssen Biotech Inc | Differentiation of pancreatic endoderm cells. |
MX340952B (es) | 2009-07-20 | 2016-07-29 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionarias humanas. |
AR078805A1 (es) | 2009-10-29 | 2011-12-07 | Centocor Ortho Biotech Inc | Celulas madre pluripotentes |
RU2610176C2 (ru) | 2009-12-23 | 2017-02-08 | Янссен Байотек, Инк. | Дифференцировка человеческих эмбриональных стволовых клеток |
KR101923537B1 (ko) * | 2009-12-23 | 2018-11-29 | 얀센 바이오테크 인코포레이티드 | 인간 배아 줄기 세포의 분화 |
MX358451B (es) * | 2010-03-01 | 2018-08-20 | Janssen Biotech Inc | Métodos para purificar células derivadas de células madre pluripotenciales. |
CN107338217B (zh) | 2010-05-12 | 2021-02-09 | 詹森生物科技公司 | 人胚胎干细胞的分化 |
KR20130100122A (ko) | 2010-08-12 | 2013-09-09 | 얀센 바이오테크 인코포레이티드 | 췌장 내분비 전구 세포를 이용한 당뇨병의 치료 |
EP2853589B1 (en) | 2010-08-31 | 2017-12-27 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
US9506036B2 (en) | 2010-08-31 | 2016-11-29 | Janssen Biotech, Inc. | Differentiation of human embryonic stem cells |
AU2011296383B2 (en) | 2010-08-31 | 2016-03-10 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
EP2646543A4 (en) | 2010-12-02 | 2014-09-03 | Technion Res & Dev Foundation | METHOD FOR GENERATING CORNEAL CELLS AND CELL POPULATIONS COMPRISING THE SAME |
US9404087B2 (en) | 2010-12-15 | 2016-08-02 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
MX2014007744A (es) | 2011-12-22 | 2015-01-12 | Janssen Biotech Inc | Diferenciacion de celulas madre embrionicas humanas en celulas individuales positivas de insulina hormonal. |
SG11201405052RA (en) | 2012-03-07 | 2014-10-30 | Janssen Biotech Inc | Defined media for expansion and maintenance of pluripotent stem cells |
WO2013162027A1 (ja) | 2012-04-27 | 2013-10-31 | 学校法人 慶應義塾 | 神経分化促進剤 |
SG11201408124PA (en) | 2012-06-08 | 2015-01-29 | Janssen Biotech Inc | Differentiation of human embryonic stem cells into pancreatic endocrine cells |
BR112015015714A2 (pt) | 2012-12-31 | 2017-07-11 | Janssen Biotech Inc | suspensão e aglomeração de células pluripotentes humanas para diferenciação em célu-las endócrinas pancreáticas |
WO2014105543A1 (en) | 2012-12-31 | 2014-07-03 | Janssen Biotech, Inc. | Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells |
US10370644B2 (en) | 2012-12-31 | 2019-08-06 | Janssen Biotech, Inc. | Method for making human pluripotent suspension cultures and cells derived therefrom |
KR101942769B1 (ko) | 2012-12-31 | 2019-01-28 | 얀센 바이오테크 인코포레이티드 | Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화 |
WO2014159662A1 (en) | 2013-03-13 | 2014-10-02 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
AU2015259573B2 (en) | 2014-05-16 | 2021-03-18 | Janssen Biotech, Inc. | Use of small molecules to enhance MAFA expression in pancreatic endocrine cells |
DK3368052T3 (da) | 2015-10-27 | 2022-03-14 | Childrens Hospital Med Ct | Anvendelse af mapk-hæmmere for at nedbringe tabet af hæmatopoietiske stamceller under ex vivo-dyrkning og -genmanipulation |
IL293289B2 (en) | 2015-11-30 | 2024-04-01 | Kadimastem Ltd | Methods for differentiation and purification of pancreatic endocrine cells |
MA45479A (fr) | 2016-04-14 | 2019-02-20 | Janssen Biotech Inc | Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen |
AU2018346712B2 (en) | 2017-10-05 | 2021-04-01 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
JP7356450B2 (ja) * | 2018-01-05 | 2023-10-04 | サイブレクサ 1・インコーポレイテッド | 酸性または低酸素の疾患組織を含む疾患の治療のための化合物、組成物、及び方法 |
JP2021519334A (ja) | 2018-03-26 | 2021-08-10 | クリア クリーク バイオ, インコーポレイテッド | ジヒドロオロト酸デヒドロゲナーゼを阻害するための組成物および方法 |
IL300393A (en) | 2020-08-21 | 2023-04-01 | Univ Miami | Preparations and treatment methods using microvesicles from mesenchymal stem cells derived from bone marrow |
US20230390341A1 (en) | 2022-04-19 | 2023-12-07 | University Of Miami | Methods and compositions for prevention and treatment of graft versus host disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4973690A (en) * | 1988-04-12 | 1990-11-27 | Ciba-Geigy Corporation | Novel ureas |
US4966622A (en) | 1988-04-12 | 1990-10-30 | Ciba-Geigy Corporation | N-phenyl-N-pyrimidin-2-ylureas |
US5559137A (en) | 1994-05-16 | 1996-09-24 | Smithkline Beecham Corp. | Compounds |
AU709370B2 (en) | 1995-01-12 | 1999-08-26 | Smithkline Beecham Corporation | Novel compounds |
US6096748A (en) * | 1996-03-13 | 2000-08-01 | Smithkline Beecham Corporation | Pyrimidine compounds useful in treating cytokine mediated diseases |
US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6242569B1 (en) * | 1997-02-05 | 2001-06-05 | Tularik, Inc. | Regulators of apoptosis |
BR9809451A (pt) * | 1997-05-22 | 2000-06-20 | Searle & Co | Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38. |
EP2036891A3 (en) * | 2001-06-11 | 2009-03-25 | Vertex Pharmaceuticals Incorporated | Isoquinoline inhibitors of P38 |
-
1999
- 1999-05-10 MY MYPI99001841A patent/MY132496A/en unknown
- 1999-05-11 CA CA2331460A patent/CA2331460C/en not_active Expired - Fee Related
- 1999-05-11 EE EEP200000610A patent/EE200000610A/xx unknown
- 1999-05-11 GE GEAP19995666A patent/GEP20032954B/en unknown
- 1999-05-11 NZ NZ508653A patent/NZ508653A/en not_active IP Right Cessation
- 1999-05-11 EP EP10177856A patent/EP2336111A1/en not_active Withdrawn
- 1999-05-11 JP JP2000548306A patent/JP4704560B2/ja not_active Expired - Fee Related
- 1999-05-11 KR KR1020007012601A patent/KR100696219B1/ko not_active IP Right Cessation
- 1999-05-11 EP EP08021820A patent/EP2062879A1/en not_active Withdrawn
- 1999-05-11 CZ CZ20004172A patent/CZ300702B6/cs not_active IP Right Cessation
- 1999-05-11 WO PCT/US1999/010291 patent/WO1999058502A1/en not_active Application Discontinuation
- 1999-05-11 IL IL13947999A patent/IL139479A0/xx unknown
- 1999-05-11 EP EP99920427A patent/EP1077943B1/en not_active Expired - Lifetime
- 1999-05-11 AP APAP/P/2000/001996A patent/AP2000001996A0/en unknown
- 1999-05-11 ES ES99920427T patent/ES2318893T3/es not_active Expired - Lifetime
- 1999-05-11 UA UA2000127087A patent/UA74325C2/uk unknown
- 1999-05-11 PT PT99920427T patent/PT1077943E/pt unknown
- 1999-05-11 AU AU37923/99A patent/AU764047B2/en not_active Ceased
- 1999-05-11 SK SK1688-2000A patent/SK286689B6/sk not_active IP Right Cessation
- 1999-05-11 CN CN99807647A patent/CN1306512A/zh active Pending
- 1999-05-11 AT AT99920427T patent/ATE417828T1/de active
- 1999-05-11 DE DE69940115T patent/DE69940115D1/de not_active Expired - Lifetime
- 1999-05-11 HU HU0105174A patent/HUP0105174A3/hu unknown
- 1999-05-11 EA EA200001176A patent/EA200001176A1/ru unknown
- 1999-05-11 PL PL344046A patent/PL198352B1/pl not_active IP Right Cessation
- 1999-05-11 DK DK99920427T patent/DK1077943T3/da active
- 1999-05-11 BR BR9911786-0A patent/BR9911786A/pt not_active Application Discontinuation
- 1999-05-11 TW TW088107631A patent/TWI249527B/zh not_active IP Right Cessation
-
2000
- 2000-11-05 IL IL139479A patent/IL139479A/en not_active IP Right Cessation
- 2000-11-10 NO NO20005673A patent/NO319755B1/no not_active IP Right Cessation
- 2000-11-10 IS IS5711A patent/IS5711A/is unknown
- 2000-12-07 BG BG105031A patent/BG65025B1/bg unknown
- 2000-12-21 US US09/746,722 patent/US6632945B2/en not_active Expired - Fee Related
-
2001
- 2001-08-13 HK HK01105642.0A patent/HK1034907A1/xx not_active IP Right Cessation
-
2003
- 2003-08-08 US US10/638,126 patent/US7115637B2/en not_active Expired - Fee Related
-
2006
- 2006-05-08 US US11/430,512 patent/US7423049B2/en not_active Expired - Fee Related
-
2008
- 2008-08-01 US US12/184,996 patent/US20090075981A1/en not_active Abandoned
-
2010
- 2010-03-12 JP JP2010056785A patent/JP2010150282A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20005673D0 (no) | Heterocykliske inhibitorer av P38 | |
DK1114051T3 (da) | Inhibitorer for p38 | |
DE69716615T2 (de) | Heterozyklische metalloproteaseinhibitoren | |
ID22982A (id) | PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38 | |
ATE231132T1 (de) | Heterocyclische metalloprotease inhibitoren | |
EE200100268A (et) | Asendatud pürasoolid p38 kinaasi inhibiitoritena | |
DK1042307T3 (da) | Aminothiazolinhibitorer af cyclinafhængige kinaser | |
NO20004217D0 (no) | Inhibitorer av fosfolipase A2 | |
EE200100044A (et) | Heterotsüklilised ühendid kui rotamaasensüümide inhibiitorid | |
CY2012029I1 (el) | Νεα μορφη της s-ομεπραζολης | |
NO20002121D0 (no) | Benzotiazol-protein-tyrosin-kinaseinhibitorer | |
DK1064298T3 (da) | Inhibitorer af caspaser | |
NO20014535D0 (no) | Inhibitorer av IMPDH-enzym | |
DK0951467T3 (da) | Substituerede nitrogenholdige heterocykliske forbindelser som inhibitorer af p38-proteinkinase | |
IS5772A (is) | Þalazín (phthalazine) afleiður af fosfódíesterasa4 lötum | |
BR9508380A (pt) | Derivados de azalonas heterocíclicos anti-helicobacter | |
ATE252547T1 (de) | Matrixmetalloproteinaseinhibitoren | |
NO20022682D0 (no) | Heterosykliske derivater | |
DK1140984T3 (da) | Selektive inhibitorer af MMP-12 | |
FI941265A (fi) | Heterosyklisiä sulfoniamidotrombiini-inhibiittoreita | |
NO940997D0 (no) | Guanidinyl-substituerte heterocykliske trombin-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |